Bristol-Myers Squibb Co. (BMY) and the Gladstone Institutes announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.
As per the agreement, Bristol-Myers Squibb will fund Gladstone's research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cell's internal skeleton and may help regulate the activity of brain cells.
In Alzheimer's disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.